Obsessive-compulsive disorder is one of the most treatment-resistant conditions in psychiatry. While cognitive behavioral therapy — specifically exposure and response prevention — and serotonin reuptake inhibitors remain the established first-line approaches, a significant portion of OCD patients achieve only partial symptom relief. For practices treating this population, transcranial magnetic stimulation offers a clinically meaningful option that is no longer experimental. TMS treatment for OCD has received FDA clearance, making it one of the few non-pharmacological interventions for the condition with a formal regulatory designation behind it.
This post breaks down the neurological basis for TMS in OCD, what the FDA clearance means in practical terms, and what psychiatric practices should consider when evaluating whether to add this capability to their treatment offerings.
The Neuroscience Behind OCD and TMS
OCD is now well understood to involve dysfunction in the cortico-striato-thalamo-cortical circuit — a loop connecting the prefrontal cortex, striatum, thalamus, and back to the cortex. Hyperactivity in this circuit, particularly in the orbitofrontal cortex and anterior cingulate cortex, is associated with the intrusive thoughts and compulsive behaviors that characterize the disorder. Medications and CBT work to interrupt this loop through different mechanisms, but they don’t work for everyone.
TMS addresses this circuitry directly. Deep TMS protocols, in particular, use an H-coil design to reach deeper cortical structures — including the medial prefrontal cortex and anterior cingulate cortex — that are implicated in OCD symptom generation. By applying repetitive magnetic stimulation to these regions, TMS can modulate the hyperactive circuitry without medication, without sedation, and without the systemic side effects that complicate pharmacological treatment in many patients. Researchers continue to refine our understanding of the precise mechanisms involved, and the National Institutes of Health maintains a growing body of peer-reviewed literature on TMS and OCD neuroscience.
FDA Clearance: What It Means for Your Practice
In 2018, the FDA cleared deep TMS using the BrainsWay H7 coil as an adjunctive treatment for OCD in adults — a meaningful regulatory milestone that distinguishes TMS for OCD from many other off-label applications. This clearance was based on a multicenter randomized controlled trial demonstrating statistically significant reductions in OCD symptom severity compared to sham treatment.
For practices, FDA clearance carries real-world implications. It supports medical necessity documentation for insurance purposes, strengthens informed consent conversations with patients, and provides a defensible clinical rationale for offering the treatment. It also signals to patients and referring providers that this is not a fringe intervention — it is a cleared medical treatment backed by controlled clinical evidence.
Practices should note that the clearance is specific to deep TMS protocols using the appropriate coil configuration. Standard figure-eight TMS coils used in depression treatment reach different cortical depths and are not interchangeable for OCD indications. Equipment selection and protocol fidelity matter when offering TMS for OCD, which makes working with a knowledgeable distributor an important part of the process. HealthTech USA’s team can walk practices through equipment considerations specific to OCD treatment — visit our products page to explore available options.
How TMS for OCD Fits Into an Existing Treatment Model
FDA clearance designates TMS as an adjunctive treatment for OCD, meaning it is intended to be used alongside ongoing therapy and medication rather than as a standalone replacement. In practice, this integrates well with how most psychiatric practices already manage OCD patients — those pursuing TMS are typically already engaged in ERP therapy or on a medication regimen, and TMS is added to the protocol for patients who need additional symptom relief.
Some clinicians have explored sequencing TMS sessions before ERP therapy appointments, with the rationale that reducing symptom severity through TMS may improve a patient’s capacity to engage productively in behavioral treatment. While the evidence on combined sequencing protocols is still developing, the general principle of TMS as a neurological complement to psychotherapy is consistent with how the treatment is used in depression and PTSD as well.
For practices with existing TMS infrastructure for depression, adding OCD as an indication is largely a matter of ensuring the appropriate coil and protocol are in place, and that clinical staff are trained on the specific deep TMS approach. HealthTech USA provides service and support to help practices expand their TMS capabilities efficiently.
Patient Selection and Expectations
Not every OCD patient is an ideal TMS candidate, and setting appropriate expectations is important for both clinical and practice management reasons. TMS for OCD tends to be most relevant for patients who have tried and had inadequate response to at least one SRI medication and a course of ERP therapy. Patients with contraindications to TMS — such as implanted metal devices near the head or a history of seizures — are generally not candidates regardless of their OCD diagnosis.
Response rates in clinical trials have been meaningful but not universal, which mirrors the broader reality of OCD treatment. Practices should communicate realistic outcome expectations clearly during the consultation process. For patients who do respond, the reduction in obsessive and compulsive symptom burden can be substantial — improving quality of life and, in many cases, improving engagement with the psychotherapy components of their care.
Adding TMS for OCD to Your Practice
The combination of FDA clearance, a clear neurological rationale, and a large underserved patient population makes TMS for OCD one of the more compelling reasons for psychiatric practices to invest in or expand their TMS capabilities. If your practice is already treating OCD patients with limited success on conventional approaches, this is a practical next step worth evaluating seriously.
HealthTech USA works with psychiatric practices across Texas and the broader United States to identify the right TMS equipment for their clinical needs and to provide ongoing technical support after installation. To learn more or to discuss which equipment configuration is appropriate for OCD treatment at your practice, explore our TMS product offerings or connect with our team through the services page.